Company news

Shanghai Henlius Biotech, Inc. news in 2026

Shanghai Henlius Biotech, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Voluntary announcement - the application for the phase 1 clinical trial of HLX105 for injection (anti-PD-1 antibody-IL-2 variant fusion protein) for the treatment of advanced/metastatic solid tumours has been approved by the national medical products administration

November 16, 2026

Voluntary announcement - inclusion of HANSIZHUANG (serplulimab injection) and others in the national reimbursement drug list

November 15, 2026

Voluntary announcement - the phase 1 clinical trial of HLX109 injection (a monoclonal antibody targeting IL1RAP) for the treatment of generalized pustular psoriasis has been approved to commence in australia

November 4, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

November 3, 2026

Documents on Display - CONTINUING CONNECTED TRANSACTION - REVISION OF ANNUAL CAP FOR THE COLLABORATION ARRANGEMENTS UNDER THE HLX01 AGREEMENT

November 2, 2026

Proxy form for the 2026 first extraordinary general meeting to be held on Monday, 23 November 2026 (or any adjournment thereof)

November 2, 2026

Notice of extraordinary general meeting

November 2, 2026

(1) Continuing connected transaction revision of annual cap for the collaboration arrangements under the HLX01 agreement (2) proposed appointment of non-executive director and independent non-executive director and notice of extraordinary general meeting

November 2, 2026

Continuing connected transaction - revision of annual cap for the collaboration arrangements under the HLX01 agreement

October 27, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 6, 2026

List of directors and their roles and functions

September 30, 2026

(1) Changes in non-executive director and independent non-executive director (2) appointment of chairman of the board and changes in composition of the board committees

September 30, 2026

Interim report 2026

September 24, 2026

Voluntary announcement - collaboration and license agreement with amberstone for two T Cell Engager products

September 23, 2026

Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation

August 21, 2026

Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC

August 21, 2026

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

August 17, 2026

FDA Approves Shanghai Henlius Biotech IND For Cetuximab Biosimilar

May 28, 2026

Henlius Announces IND Approval from NMPA for Its Proprietary c-Met/EGFR Bispecific ADC HLX48

May 22, 2026

European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

April 29, 2026

NMPA Grants IND Approval for Henlius Nivolumab Biosimilar HLX18 Following U.S. FDA Clearance

March 23, 2026

Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations

March 20, 2026

Henlius Obtains Japan MAH License Strengthening Presence in the World's Fourth-Largest Pharmaceutical Market

March 2, 2026

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

February 5, 2026

Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026

January 16, 2026

Henlius Fifth U.S. Filing Product Bevacizumab Biosimilar HLX04 Receives FDA BLA Acceptance

January 14, 2026

Decks in 2026